SCHEMBL23590236

SCHEMBL23590236

COCc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(C(F)(F)F)ccc4n3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 9/20 0.53
▸ HSD17B10 Q99714 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ PTGES O14684 1/20 0.50
▸ ALOX5 P09917 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ EIF4A1 P60842 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ EPRS1 P07814 1/20 0.48
▸ CDK2 P24941 2/20 0.47
▸ TP53 P04637 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074194 0.92 PLA2G2A (0.55) DHODHALDH1A1KDM4E
SCHEMBL23590233 0.91 DHODH (0.51) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL23590328 0.90 HIF1A (0.51) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL25118616 0.90 DHODH (0.46) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL26073768 0.89 DHODH (0.47) DHODHHSD17B10EIF4A1KDM4ECDK2
SCHEMBL23590078 0.86 KDM4E (0.65) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL29617667 0.85 DHODH (0.70) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL23590321 0.85 DHODH (0.70) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL6181595 0.85 ALDH1A1 (0.59) DHODHHSD17B10ALDH1A1HIF1APTGES
SCHEMBL23590234 0.85 DHODH (0.52) DHODHHSD17B10ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885HSD17B10 165/4885ALDH1A1 72/4885
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885HSD17B10 130/4885ALDH1A1 88/4885
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885HSD17B10 172/4885ALDH1A1 64/4885
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885HSD17B10 165/4885ALDH1A1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback